Skip to main content
SpringerLink
Log in

Circulating Tumor Cells as Biomarkers in Pancreatic Cancer

  • Chapter
  • First Online:
Translational Pancreatic Cancer Research

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 368 Accesses

Abstract

Metastatic disease is the cause of mortality in most patients with pancreatic cancer. Circulating tumor cells (CTCs) play an important role in the establishment of metastases, can be subcategorized and correlated with patient outcomes, and offer an opportunity to view the course of disease in real time. This chapter gives an overview of the merit of CTCs as a biomarker and reflects on the potential these cells may have to both contribute to novel, precision therapies for pancreatic cancer and serve as a form of liquid biopsy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013. Cancer Epidemiol Biomark Prev. 2017;26(4):632–41. https://doi.org/10.1158/1055-9965.EPI-16-0520.

    Article  Google Scholar 

  2. Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267(5):936–45. https://doi.org/10.1097/SLA.0000000000002234.

    Article  PubMed  Google Scholar 

  3. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52. https://doi.org/10.1038/nature16965.

    Article  CAS  PubMed  Google Scholar 

  5. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501. https://doi.org/10.1038/nature14169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–3. https://doi.org/10.1038/nm.2344.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2003;162(4):1151–62. https://doi.org/10.1016/S0002-9440(10)63911-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–78. https://doi.org/10.1038/ng.3398.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Pan S, Brentnall TA, Kelly K, Chen R. Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges. Proteomics. 2013;13:710–21. https://doi.org/10.1002/pmic.201200319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cohen JD, Javed AA, Thoburn C, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A. 2017;114(38):10202–7. https://doi.org/10.1073/PNAS.1704961114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol. 2002;160(1):91–9. https://doi.org/10.1016/S0002-9440(10)64353-2.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Laklai H, Miroshnikova YA, Pickup MW, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2016;22(5):497–505. https://doi.org/10.1038/nm.4082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457–61. https://doi.org/10.1126/science.1171362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Beatty GL, Eghbali S, Kim R. Deploying immunotherapy in pancreatic cancer: defining mechanisms of response and resistance. Am Soc Clin Oncol Educ Book. 2017;37:267–78. https://doi.org/10.14694/edbk_175232.

    Article  PubMed  Google Scholar 

  15. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA. HER2/neu expression in malignant lung tumors. Semin Oncol. 2002;29(1 Suppl 4):51–8.

    Article  CAS  PubMed  Google Scholar 

  16. Chand P, Anubha G, Singla V, Rani N. Evaluation of immunohistochemical profile of breast cancer for prognostics and therapeutic use. Niger J Surg. 2018;24(2):100. https://doi.org/10.4103/njs.NJS_2_18.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–30. https://doi.org/10.1126/science.aar3247.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Cristofanilli M, Fortina P. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;369(1):93–4. https://doi.org/10.1056/NEJMc1306040.

    Article  PubMed  Google Scholar 

  19. Perets R, Greenberg O, Shentzer T, et al. Mutant KRAS circulating tumor DNA is an accurate tool for pancreatic cancer monitoring. Oncologist. 2018;23(5):566–72. https://doi.org/10.1634/theoncologist.2017-0467.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71–88. https://doi.org/10.1038/s41576-018-0071-5.

    Article  CAS  PubMed  Google Scholar 

  21. Dong X, Alpaugh KR, Cristofanilli M. Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. Chin J Cancer Res. 2012;24(4):388–98. https://doi.org/10.3978/j.issn.1000-9604.2012.11.03.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Buim ME, Fanelli MF, Souza VS, et al. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biol Ther. 2015;16(9):1289–95. https://doi.org/10.1080/15384047.2015.1070991.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yu M, Ting DT, Stott SL, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012;487(7408):510–3. https://doi.org/10.1038/nature11217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Woo D, Yu M. Circulating tumor cells as “liquid biopsies” to understand cancer metastasis. Transl Res. 2018;201:128–35. https://doi.org/10.1016/j.trsl.2018.07.003.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australas Med J. 1869;14:146–9. http://ci.nii.ac.jp/naid/10029590080/en/. Accessed 28 Dec 2018.

    Google Scholar 

  26. DiPardo BJ, Winograd P, Court CM, Tomlinson JS. Pancreatic cancer circulating tumor cells: applications for personalized oncology. Expert Rev Mol Diagn. 2018;18(9):809–20. https://doi.org/10.1080/14737159.2018.1511429.

    Article  CAS  PubMed  Google Scholar 

  27. Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529(7586):298–306. https://doi.org/10.1038/nature17038.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–4. https://doi.org/10.1126/science.1228522.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Poruk KE, Valero V 3rd, Saunders T, et al. Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma. Ann Surg. 2016;264(6):1073–81. https://doi.org/10.1097/SLA.0000000000001600.

    Article  PubMed  Google Scholar 

  30. Gemenetzis G, Groot VP, Yu J, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective CLUSTER study. Ann Surg. 2018;268(3):408–20. https://doi.org/10.1097/SLA.0000000000002925.

    Article  PubMed  Google Scholar 

  31. Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110–22. https://doi.org/10.1016/j.cell.2014.07.013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10(24):8152–62. https://doi.org/10.1158/1078-0432.CCR-04-1110.

    Article  PubMed  Google Scholar 

  33. Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16(9):553–65. https://doi.org/10.1038/nrc.2016.66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease – latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–24. https://doi.org/10.1038/s41571-019-0187-3.

    Article  CAS  PubMed  Google Scholar 

  35. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47(20):5501–3.

    CAS  PubMed  Google Scholar 

  36. Poruk KE, Gay DZ, Brown K, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13(3):340–51. https://doi.org/10.2174/1566524011313030003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–70. https://doi.org/10.1016/j.ejso.2006.10.004.

    Article  CAS  PubMed  Google Scholar 

  38. Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2016;35(10):1216–24. https://doi.org/10.1038/onc.2015.192.

    Article  CAS  PubMed  Google Scholar 

  39. Bidard FC, Huguet F, Louvet C, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol. 2013;24(8):2057–61. https://doi.org/10.1093/annonc/mdt176.

    Article  CAS  PubMed  Google Scholar 

  40. Kurihara T, Itoi T, Sofuni A, et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepato-Biliary-Pancreat Surg. 2008;15(2):189–95. https://doi.org/10.1007/s00534-007-1250-5.

    Article  Google Scholar 

  41. de Albuquerque A, Kubisch I, Breier G, et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology. 2012;82(1):3–10. https://doi.org/10.1159/000335479.

    Article  CAS  PubMed  Google Scholar 

  42. Bhagwat N, Dulmage K, Pletcher CH, et al. An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Sci Rep. 2018;8:5035. https://doi.org/10.1038/s41598-018-23217-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells. Am J Pathol. 2000;156(1):57–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Pimienta M, Edderkaoui M, Wang R, Pandol S. The potential for circulating tumor cells in pancreatic cancer management. Front Physiol. 2017;8:1–13. https://doi.org/10.3389/fphys.2017.00381.

    Article  Google Scholar 

  45. Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14(9):623–31. https://doi.org/10.1038/nrc3820.

    Article  CAS  PubMed  Google Scholar 

  46. Zhang Z, Shiratsuchi H, Lin J, et al. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget. 2014;5(23):12383–97. https://doi.org/10.18632/oncotarget.2592.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9. https://doi.org/10.1038/nature06385.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Rox JM, Stoecklein NH, Kasprowicz NS, et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A. 2013;110(41):16580–5. https://doi.org/10.1073/pnas.1313594110.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Luk AWS, Ma Y, Ding PN, et al. CTC-mRNA (AR-V7) analysis from blood samples – impact of blood collection tube and storage time. Int J Mol Sci. 2017;18(5):1047. https://doi.org/10.3390/ijms18051047.

    Article  CAS  PubMed Central  Google Scholar 

  50. Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clin Cancer Res. 2007;13(3):920–8. https://doi.org/10.1158/1078-0432.CCR-06-1695.

    Article  CAS  PubMed  Google Scholar 

  51. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011;129(7):1651–60. https://doi.org/10.1002/ijc.25819.

    Article  CAS  PubMed  Google Scholar 

  52. Hou JM, Krebs M, Ward T, et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 2011;178(3):989–96. https://doi.org/10.1016/j.ajpath.2010.12.003.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012;18(20):5701–10. https://doi.org/10.1158/1078-0432.CCR-12-1587.

    Article  PubMed  Google Scholar 

  54. Helissey C, Berger F, Cottu P, et al. Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. Cancer Lett. 2015;360(2):213–8. https://doi.org/10.1016/j.canlet.2015.02.010.

    Article  CAS  PubMed  Google Scholar 

  55. Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13(7):688–95. https://doi.org/10.1016/S1470-2045(12)70209-7.

    Article  PubMed  Google Scholar 

  56. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91. https://doi.org/10.1056/NEJMoa040766.

    Article  CAS  PubMed  Google Scholar 

  57. Tarhan MO, Gonel A, Kucukzeybek Y, et al. Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev. 2013;14(3):1725–9.

    Article  PubMed  Google Scholar 

  58. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32(31):1–8. https://doi.org/10.1200/JCO.2014.56.2561.

    Article  CAS  Google Scholar 

  59. Hiltermann TJN, Pore MM, van den Berg A, et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol. 2012;23(11):2937–42. https://doi.org/10.1093/annonc/mds138.

    Article  CAS  PubMed  Google Scholar 

  60. Hou J-M, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30(5):525–32. https://doi.org/10.1200/jco.2010.33.3716.

    Article  PubMed  Google Scholar 

  61. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res. 2011;17(4):827–35. https://doi.org/10.1158/1078-0432.CCR-10-0445.

    Article  CAS  PubMed  Google Scholar 

  62. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366–77. https://doi.org/10.1056/NEJMoa0800668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Yang JD, Campion MB, Liu MC, et al. Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology. 2016;63(1):148–58. https://doi.org/10.1002/hep.27944.

    Article  PubMed  Google Scholar 

  64. Cohen SJ, Punt CJA, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–21. https://doi.org/10.1200/JCO.2007.15.8923.

    Article  PubMed  Google Scholar 

  65. Uen Y-H, Lu C-Y, Tsai H-L, et al. Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol. 2008;15(8):2120–8. https://doi.org/10.1245/s10434-008-9961-7.

    Article  PubMed  Google Scholar 

  66. Aggarwal C, Meropol NJ, Punt CJ, et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol. 2013;24(2):420–8. https://doi.org/10.1093/annonc/mds336.

    Article  CAS  PubMed  Google Scholar 

  67. van Dalum G, Stam GJ, Scholten LF, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol. 2015;46(3):1361–8. https://doi.org/10.3892/ijo.2015.2824.

    Article  CAS  PubMed  Google Scholar 

  68. Kaifi JT, Kunkel M, Das A, et al. Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques. Cancer Biol Ther. 2015;16(5):699–708. https://doi.org/10.1080/15384047.2015.1030556.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Mazzini C, Pinzani P, Salvianti F, et al. Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method. Cancers (Basel). 2014;6(1):323–32. https://doi.org/10.3390/cancers6010323.

    Article  CAS  Google Scholar 

  70. Goodman OB, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin Genitourin Cancer. 2011;9(1):31–8. https://doi.org/10.1016/j.clgc.2011.04.001.

    Article  PubMed  Google Scholar 

  71. Wang F-B, Yang XQ, Yang S, Wang BC, Feng MH, Tu JC. A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients – a meta-analysis. Asian Pac J Cancer Prev. 2011;12(10):2629–35.

    PubMed  Google Scholar 

  72. Zhang Y, Wang F, Ning N, et al. Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer. Int J Cancer. 2015;136(5):1228–33. https://doi.org/10.1002/ijc.29070.

    Article  CAS  PubMed  Google Scholar 

  73. Ma XL, Li YY, Zhang J, et al. Prognostic role of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(15):6015–20. https://www.ncbi.nlm.nih.gov/pubmed/25124566.

    Article  PubMed  Google Scholar 

  74. Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35(3):2473–80. https://doi.org/10.1007/s13277-013-1327-5.

    Article  CAS  PubMed  Google Scholar 

  75. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells – an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005;5(9):744–9. https://doi.org/10.1038/nrc1694.

    Article  CAS  PubMed  Google Scholar 

  76. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15. https://doi.org/10.1016/j.cell.2008.03.027.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008;3(8):e2888. https://doi.org/10.1371/journal.pone.0002888.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–61. https://doi.org/10.1016/j.cell.2011.11.025.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90. https://doi.org/10.1016/j.cell.2009.11.007.

    Article  CAS  PubMed  Google Scholar 

  80. Handra-Luca A, Hong SM, Walter K, Wolfgang C, Hruban R, Goggins M. Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas. Br J Cancer. 2011;104(8):1296–302. https://doi.org/10.1038/bjc.2011.93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011;13(3):R59. https://doi.org/10.1186/bcr2896.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Planchard D, Farace F, Soria JC, Vielh P, Perez-Moreno P, Lecharpentier A. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer. 2011;105(9):1338–41. https://doi.org/10.1038/bjc.2011.405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Armstrong AJ, Marengo MS, Oltean S, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2012;9(8):997–1007. https://doi.org/10.1158/1541-7786.MCR-10-0490.Circulating.

    Article  Google Scholar 

  84. Gkountela S, Aceto N. Stem-like features of cancer cells on their way to metastasis. Biol Direct. 2016;11:1–14. https://doi.org/10.1186/s13062-016-0135-4.

    Article  Google Scholar 

  85. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14(3):275–91. https://doi.org/10.1016/j.stem.2014.02.006.

    Article  CAS  PubMed  Google Scholar 

  86. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol. 2008;26(17):2806–12. https://doi.org/10.1200/JCO.2008.16.6702.

    Article  PubMed  Google Scholar 

  87. Cauley CE, Pitman MB, Zhou J, et al. Circulating epithelial cells in patients with pancreatic lesions: clinical and pathologic findings. J Am Coll Surg. 2015;221(3):699–707. https://doi.org/10.1016/j.jamcollsurg.2015.05.014.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Franken B, de Groot MR, Mastboom WJ, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012;14(5):R133. https://doi.org/10.1186/bcr3333.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Pantel K, Deneve E, Nocca D, et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 2012;58(5):936–40. https://doi.org/10.1373/clinchem.2011.175570.

    Article  CAS  PubMed  Google Scholar 

  90. Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32(5):479–84. https://doi.org/10.1038/nbt.2892.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013;73(10):2965–75. https://doi.org/10.1158/0008-5472.CAN-12-4140.

    Article  CAS  PubMed  Google Scholar 

  92. Ni X, Zhuo M, Su Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A. 2013;110(52):21083–8. https://doi.org/10.1073/pnas.1320659110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Vanharanta S, Massagué J. Origins of metastatic traits. Cancer Cell. 2013;24(4):410–21. https://doi.org/10.1016/j.ccr.2013.09.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Court CM, Ankeny JS, Sho S, et al. Reality of single circulating tumor cell sequencing for molecular diagnostics in pancreatic cancer. J Mol Diagn. 2016;18(5):688–96. https://doi.org/10.1016/j.jmoldx.2016.03.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Kulemann B, Liss AS, Warshaw AL, et al. KRAS mutations in pancreatic circulating tumor cells: a pilot study. Tumor Biol. 2016;37(6):7547–54. https://doi.org/10.1007/s13277-015-4589-2.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Johns Hopkins Medical Institution, Baltimore, MD, USA

    Alina Hasanain

  2. Division of Surgical Oncology, Department of Surgery, Pathology and Oncology, Johns Hopkins Medical Institution, Baltimore, MD, USA

    Christopher L. Wolfgang

Authors
  1. Alina Hasanain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher L. Wolfgang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher L. Wolfgang .

Editor information

Editors and Affiliations

  1. Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Christoph W. Michalski

  2. Department of Internal Medicine I, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Jonas Rosendahl

  3. Department of Internal Medicine I, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Patrick Michl

  4. Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Jörg Kleeff

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hasanain, A., Wolfgang, C.L. (2020). Circulating Tumor Cells as Biomarkers in Pancreatic Cancer. In: Michalski, C., Rosendahl, J., Michl, P., Kleeff, J. (eds) Translational Pancreatic Cancer Research. Molecular and Translational Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-49476-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-49476-6_9

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-49475-9

  • Online ISBN: 978-3-030-49476-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation